Clinigence Holdings (NUTX) AI Stock Analysis

• Market Cap: $1.30B
• Dividend Yield: N/A
• Average Volume (3M): 159.36K
• Price to Earnings (P/E): 9.6
• Beta (1Y): 2.04
• Revenue Growth: 236.03%
• EPS Growth: N/A
• Country: US
• Employees: 800
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): N/A
• Shares Outstanding: 7,071,916
• 10 Day Avg. Volume: 134,698
• 30 Day Avg. Volume: 159,364
• PEG Ratio: -0.02
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.34
• P/FCF Ratio: 7.75
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $265.00
• Price Target Upside: 138.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: $203.00 ▲(82.88% Upside)

Nutex Health's strong financial performance and significant revenue growth are major positives, supported by bullish technical indicators. However, overbought signals, dependence on arbitration revenue, and legal challenges present potential risks. The stock's valuation is attractive, but the lack of a dividend yield may deter some investors.

Positive Factors

Revenue Growth

Significant revenue growth indicates strong market demand and effective business strategies, enhancing long-term financial stability.

Cash Flow Generation

Strong cash flow generation supports operational flexibility and investment capacity, crucial for sustainable growth.

Operational Efficiency

High gross profit margins reflect efficient operations, enabling the company to maintain competitive pricing and invest in growth.

Negative Factors

Dependence on Arbitration Revenue

Heavy reliance on arbitration revenue introduces risk if regulatory or market conditions change, potentially impacting revenue stability.

Delayed SEC Filings

Delayed filings can erode investor confidence and lead to regulatory scrutiny, affecting the company's market perception and compliance status.

Litigation and Regulatory Concerns

Ongoing litigation and regulatory issues can distract management and incur costs, potentially impacting financial performance and strategic focus.

Clinigence Holdings Business Overview & Revenue Model

Company Description

Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.

How the Company Makes Money

Clinigence Holdings generates revenue through multiple streams, primarily by offering subscription-based services for its software platforms that help healthcare providers manage patient data and improve care coordination. The company also earns revenue from consulting services that assist healthcare organizations in implementing its technologies effectively. Additionally, partnerships with healthcare institutions and payers enhance its market reach and diversify income sources. These partnerships often lead to joint initiatives that can result in shared revenue from improved patient care outcomes and operational efficiencies.

Clinigence Holdings Financial Statement Overview

Summary

Clinigence Holdings shows strong revenue and cash flow growth, with efficient operational management. However, historical financial volatility and high leverage in previous years require cautious monitoring.

Income Statement

Clinigence Holdings has demonstrated strong revenue growth with a 23.86% increase in TTM, supported by solid gross and net profit margins of 55.01% and 11.63% respectively. The EBIT and EBITDA margins are also robust at 34.79% and 36.89%, indicating efficient operational management. However, the company has experienced fluctuations in profitability in previous years, which could pose a risk if not managed.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.75 in TTM, showing a reduction in leverage compared to previous years. The return on equity is strong at 40.80%, reflecting effective use of equity capital. However, the equity ratio is not explicitly provided, and historical high leverage ratios suggest potential financial risk if not monitored.

Cash Flow

Clinigence Holdings has shown impressive free cash flow growth of 71.03% in TTM, with a high free cash flow to net income ratio of 99.74%, indicating strong cash generation relative to earnings. The operating cash flow to net income ratio is also healthy at 95.87%. Despite these strengths, the company has faced cash flow challenges in the past, which should be considered.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	981.20M	479.95M	247.65M	219.29M	331.53M	274.03M
Gross Profit	539.77M	196.26M	34.77M	15.42M	179.28M	157.61M
EBITDA	361.94M	148.65M	-14.58M	-394.03M	183.45M	158.07M
Net Income	114.07M	52.18M	-45.79M	-424.78M	132.59M	105.97M
Balance Sheet
Total Assets	964.52M	655.32M	398.25M	431.75M	394.65M	308.55M
Cash, Cash Equivalents and Short-Term Investments	166.05M	43.58M	22.00M	34.26M	36.12M	25.51M
Total Debt	358.60M	340.30M	275.76M	267.20M	178.55M	150.12M
Total Liabilities	526.49M	453.43M	319.14M	311.42M	203.07M	161.19M
Stockholders Equity	317.17M	146.34M	61.45M	95.86M	114.65M	85.81M
Cash Flow
Free Cash Flow	224.03M	20.85M	-8.24M	35.97M	136.51M	25.48M
Operating Cash Flow	224.79M	23.15M	1.26M	50.61M	173.43M	86.67M
Investing Cash Flow	-565.25K	-2.67M	-11.24M	-4.34M	-36.98M	-61.19M
Financing Cash Flow	-55.14M	1.09M	-2.27M	-48.13M	-125.85M	-7.97M

Clinigence Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 111.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Positive. The current price of 111 is below the 20-day moving average (MA) of 173.47, below the 50-day MA of 145.91, and below the 200-day MA of 119.48, indicating a bullish trend. The MACD of 7.92 indicates Positive momentum. The RSI at 58.83 is Neutral, neither overbought nor oversold. The STOCH value of 67.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUTX.

Clinigence Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUTX	74 Outperform	$1.30B	9.55	63.86%	―	236.03%	―
HSTM	69 Neutral	$655.67M	32.39	5.87%	0.52%	3.68%	5.62%
TXG	60 Neutral	$2.44B	-30.87	-10.12%	―	1.92%	59.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HCAT	50 Neutral	$173.29M	-1.55	-31.33%	―	4.64%	-17.17%
DH	49 Neutral	$364.05M	-1.53	-47.69%	―	-5.30%	46.01%
EVH	48 Neutral	$464.26M	-2.65	-13.63%	―	-16.65%	-71.92%

Clinigence Holdings Corporate Events

Clinigence Holdings Files Auditors’ Consent for Nutex

Clinigence Holdings has filed an auditors’ consent related to Nutex Health Inc.’s consolidated financial statements for the years ending December 31, 2023. This filing, made on November 18, 2025, incorporates these financial statements into previously filed registration statements, potentially impacting stakeholders’ understanding of the company’s financial health.

The most recent analyst rating on (NUTX) stock is a Buy with a $164.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.

Clinigence Holdings Granted Extension for Nasdaq Compliance

On August 20, 2025, Clinigence Holdings received a notice from Nasdaq due to a delay in filing its quarterly report for June 30, 2025, which led to non-compliance with listing requirements. The company submitted a compliance plan on October 15, 2025, and was granted an extension until December 12, 2025, to file the report, with potential delisting if not met. Nutex Health, meanwhile, reported significant growth in patient volume and cash collections for Q3 2025, with an 11.1% increase in patient visits and a 258.8% rise in cash collections compared to the previous year, driven by strategic expansions and improved revenue management.

The most recent analyst rating on (NUTX) stock is a Buy with a $113.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.